Deutsche Venture Capital (DVC), the European life sciences and technology investor based in Germany, has made two appointments at its European life sciences team as it continues to build its team despite the downturn.
Thomas Taapken, previously director of Aventis Venture Activities, and David Karabelnik, director of Breslin Biotech, join the firm’s life sciences team as director and consultant respectively.
Taapken managed the Genavent VC fund, a E100m joint fund between Aventis and Societé Générale Asset Management. He also worked on behalf of Aventis Cropscience as venture capital manager at Burrill & Company in San Francisco.
Karabelnik was co-founder and managing director of Breslin Biotech AG, a Swiss-based VC company and partner of BdW – Dresdner-Allianz-Group.
DVC has been one of the most active recruiters in European venture capital during the last twelve months. Guy Kawasaki, Wolfgang Krause, Cyril Bertrand and Johannes Neukirchen joined the firm’s technology advisory team last year, while Rolf Krebs, Peter Gruss and Hartmut Michel have all been recuited to the firm’s life sciences advisory team.
“We have increased the number of our life sciences team members and, with the help of our advisory board members, will be able to even better and more competently support young companies,” said Jörg Neermann, managing partner at DVC.
DVC has access to the global venture capital and private equity network of Deutsche Bank, as well as partnerships with US venture capital funds, including US-based ATV Advanced Technology Ventures.
The firm invested E13.8m across eleven companies in 2002, including two investments, Avontec and Sireen, as lead investors. DVC has E300m under management of which E90m is available for further investments. Since its formation in 1998, DVC has invested in around 50 companies, of which five have successfully exited management and founders.